CANTARGIA AB
- Country
- 🇸🇪Sweden
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 22
- Market Cap
- -
- Website
- http://cantargia.com
A Study to Investigate the Safety and Tolerability of CAN10 Antibody in Healthy Subjects and in Subjects With Plaque Psoriasis.
- Conditions
- Interventions
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- Cantargia AB
- Target Recruit Count
- 80
- Registration Number
- NCT06143371
- Locations
- 🇩🇪
CRS Clinical Research Services Berlin GmbH, Berlin, Germany
Nadunolimab in Combination with Gemcitabine Plus Carboplatin in Patients with Advanced Triple Negative Breast Cancer.
- Conditions
- Interventions
- First Posted Date
- 2022-01-06
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Cantargia AB
- Target Recruit Count
- 116
- Registration Number
- NCT05181462
- Locations
- 🇪🇸
Hospital Universitario Virgen de las Nieves, Granada, Andalucía, Spain
🇪🇸Hospital Universitario Clinico San Cecilio, Granada, Andalucía, Spain
🇪🇸Complejo Hospitalario de Jaén, Jaén, Andalucía, Spain
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-11-11
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Cantargia AB
- Target Recruit Count
- 40
- Registration Number
- NCT05116891
- Locations
- 🇫🇷
Centre Georges François Leclerc, Dijon, Côte-d'Or, France
🇫🇷Institut Bergonie, Bordeaux Cedex, France
🇫🇷EDOG Institut de Cancerologie de l'Ouest - PPDS, Saint-Herblain, Boulevard Jacques Monod, France
A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-08-04
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- Cantargia AB
- Target Recruit Count
- 25
- Registration Number
- NCT04990037
- Locations
- 🇪🇸
ICO l'Hospitalet - Hospital Duran i Reynals, Barcelona, Spain
🇫🇷EDOG - Centre Eugene Marquis Centre Regional de Lutte Contre Le Cancer - PPDS, Rennes, France
🇫🇷EDOG - Institut Bergonie - PPDS, Bordeaux, France
A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors
- First Posted Date
- 2020-06-30
- Last Posted Date
- 2023-07-14
- Lead Sponsor
- Cantargia AB
- Target Recruit Count
- 19
- Registration Number
- NCT04452214
- Locations
- 🇺🇸
Florida Cancer Specialists & Research Institute, Lake Mary, Florida, United States
🇺🇸University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸Hospital of The University of Pennsylvania, Philadelphia, Pennsylvania, United States
A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors
- First Posted Date
- 2017-08-30
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Cantargia AB
- Target Recruit Count
- 167
- Registration Number
- NCT03267316
- Locations
- 🇩🇰
Rigshospitalet, Department of Oncology, Copenhagen, Denmark
🇦🇹Medizinische Universität Wien, Vienna, Austria
🇦🇹Landeskrankenhaus Salzburg, Salzburg, Austria